Drug Interactions between Didronel and Levaquin
This report displays the potential drug interactions for the following 2 drugs:
- Didronel (etidronate)
- Levaquin (levofloxacin)
Interactions between your drugs
No interactions were found between Didronel and Levaquin. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Didronel
A total of 180 drugs are known to interact with Didronel.
- Didronel is in the drug class bisphosphonates.
- Didronel is used to treat the following conditions:
Levaquin
A total of 528 drugs are known to interact with Levaquin.
- Levaquin is in the drug class quinolones and fluoroquinolones.
-
Levaquin is used to treat the following conditions:
- Anthrax
- Anthrax Prophylaxis
- Bacterial Infection
- Bladder Infection
- Bronchitis
- Chlamydia Infection
- Epididymitis, Sexually Transmitted
- Gonococcal Infection, Disseminated
- Gonococcal Infection, Uncomplicated
- Kidney Infections
- Middle Ear Infections (off-label)
- Nongonococcal Urethritis
- Nosocomial Pneumonia
- Pelvic Inflammatory Disease
- Plague
- Plague Prophylaxis
- Pneumonia
- Prostatitis
- Sinusitis
- Skin or Soft Tissue Infection
- Streptococcal Infection
- Tuberculosis, Active
- Urinary Tract Infection
Drug and food/lifestyle interactions
etidronate food/lifestyle
Applies to: Didronel (etidronate)
ADJUST DOSING INTERVAL: Food, especially calcium-containing food such as dairy products, significantly decreases the bioavailability of oral etidronate.
MANAGEMENT: Oral etidronate should be administered on an empty stomach and no other food or drink should be taken within least 2 hours of administration.
References (2)
- (2022) "Product Information. Didronel (etidronate)." Procter and Gamble Pharmaceuticals
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
levoFLOXacin food/lifestyle
Applies to: Levaquin (levofloxacin)
ADJUST DOSING INTERVAL: Food may reduce the oral absorption and bioavailability of levofloxacin. According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.
MANAGEMENT: To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals. For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin. The oral tablets may be taken without regard to food.
References (1)
- Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT (2009) "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm, 66, p. 1438-67
etidronate food/lifestyle
Applies to: Didronel (etidronate)
ADJUST DOSING INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates. For example, the bioavailability of tiludronate has been shown to decrease 80% during simultaneous administration with calcium, and 60% when aluminum- or magnesium-containing antacids were administered one hour before tiludronate.
MANAGEMENT: Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 2 hours before or 2 hours after the bisphosphonate dose.
References (6)
- (2001) "Product Information. Fosamax (alendronate)." Merck & Co., Inc
- Darcy PF (1995) "Nutrient-drug interactions." Adverse Drug React Toxicol Rev, 14, p. 233-54
- "Product Information. Skelid (tiludronate)." Sanofi Winthrop Pharmaceuticals
- (2001) "Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals
- (2001) "Product Information. Bonefos (clodronate)." Rhone-Poulenc Rorer Canada Inc
- (2005) "Product Information. Boniva (ibandronate)." Roche Laboratories
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.